Oxford & AstraZeneca COVID-19 vaccine triggers immune response
Results from the ongoing Phase I/II COVID-19 vaccine trial, led by the University of Oxford, showed the AZD1222 vaccine developed
Read moreResults from the ongoing Phase I/II COVID-19 vaccine trial, led by the University of Oxford, showed the AZD1222 vaccine developed
Read moreModerna’s COVID-19 vaccine candidate generated antibodies in all 45 patients studied in its early stage human trial, the U.S biotech
Read moreAt a time when pharma and biotech companies worldwide are racing to develop a vaccine, researchers at the University of
Read moreSanofi and GlaxoSmithKline are close to reaching a 500 million-pound ($624 million) deal to supply the United Kingdom government with
Read moreTesla Inc is engineering mobile molecule printers to help produce the future COVID-19 vaccine developed by CureVac in Germany, the
Read moreThese three pharmaceutical companies should be well shielded from the adverse effects of the looming economic downturn. According to the
Read moreThe World Health Organization (WHO) and the Democratic Republic of Congo (DRC) government announced on June 25 that the second-largest
Read moreThe Chinese company Clover Biopharmaceuticals revealed the start of a randomized, double-blind, human stage Phase I placebo-controlled clinical study to
Read moreAlgernon has received the FDA’s approval for the commencement of a Phase 2 and 3 human study of it’s repurposed
Read moreBritish pharmaceutical company AstraZeneca has reached a landmark $750 million agreement with Coalition for Epidemic Preparedness Innovation (CEPI) and the
Read more